CINCINNATI, Feb. 20, 2015 /PRNewswire/ -- Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, would like to announce that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy"), has generated additional data that bolsters its hypothesis that their genetically enhanced strain of bacteria yields increased electricity generation compared to data available in the scientific literature. Specifically, 5 days after inoculation, Pilus's pilT mutant produced a maximum current density of 60 x10^-6 watts per square centimeter, or 50% more power than the next comparable strain in the literature. The specific paper was selected for comparison because of similar experimental conditions, such as use of a platinum coated cathode, and graphite felt anode. Furthermore, Pilus believes it have solved several key hardware issues to create a more stable system, thereby serving as a foundation to conduct and fine-tune further experiments. Pilus is also completing the fabrication of five new reactors that will allow for larger scale testing.
Finally, using this new data and understanding of the technology as leverage, Pilus has been successful in initiating talks with a large wastewater technology company that could significantly speed up the time required to commercialize this technology.
Pilus Energy Co-Founder and Tauriga Advisory Board Member, Professor Daniel J. Hassett stated, "This data is very promising because it suggests that our synthetic biology and microbiology research may have produced a stable, metabolically voracious, genetically engineered strain of bacteria with significant industrial potential for remediating wastewater and converting the pollutants to value in the form of energy output."
Tauriga Chairman & CEO Stella M. Sung, Ph.D. added, "We plan on updating shareholders on our continuing efforts at Pilus Energy. The Pilus technology is extremely promising, and it is a perfect complement to our consumer natural wellness business. The Pilus milestones are necessarily longer term, given the nature of the development and commercialization processes. However, they are meaningful and quantifiable achievements."
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company's corporate website at www.tauriga.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
SOURCE Tauriga Sciences, Inc.